Breaking News Instant updates and real-time market news.

VRX

Valeant

$15.37

0.24 (1.59%)

07:07
08/08/17
08/08
07:07
08/08/17
07:07

Valeant CEO says investments in core business 'delivering results'

"The investments we are making in our core business are delivering results. The Bausch + Lomb/International segment and Salix business, which together represented 73% of our revenue in the quarter, delivered strong organic growth, and we are continuing to reduce debt and resolve legacy issues. Additionally, we confirm that we are maintaining our 2017 full-year Adjusted EBITDA guidance range despite the impact of divestitures we've made this year," said CEO Joseph Papa.

  • 08

    Aug

  • 24

    Aug

VRX Valeant
$15.37

0.24 (1.59%)

07/17/17
WELS
07/17/17
NO CHANGE
WELS
Underperform
Wells says Valeant selling Obagi for less than half of price paid in 2013
After Valeant announced it has agreed to sell its Obagi Medical Products business for $190M in cash, Wells Fargo analyst David Maris noted that this sale price is less than half of the $437M that the company paid to acquire Obagi in April 2013. While Valeant continues to make progress toward its asset sales and debt reduction targets, Maris does not believe that its recent divestitures have had a significant deleveraging impact. He keeps an Underperform rating on Valeant shares.
07/27/17
WELS
07/27/17
NO CHANGE
WELS
Underperform
Doctors not optimistic about Valeant's Siliq, says Wells Fargo
Wells Fargo analyst David Maris says the dozens of doctors he spoke to about Valeant Pharmaceuticals' Siliq are not optimistic. Over 50% of the physicians surveyed said they would use Siliq only as a fourth line therapy or later, Maris tells investors in a research note after Valeant announced the launch of the moderate-to-severe plaque psoriasis treatment. The analyst disagrees with Valeant management's claims that Siliq has "very large peak sales potential." The injection carries a warning about risk of suicide and Valeant will be competing against a large number of peers with greater resources, Maris argues. The analyst has an Underperform rating on Valeant shares, which are down 18c to $17.59 in midday trading.
07/28/17
WELS
07/28/17
NO CHANGE
Target $9
WELS
Underperform
Insurers are dropping Valeant's top products, says Wells Fargo
United Healthcare's (UNH) formulary is no longer covering Valeant Pharmaceuticals' (VRX) number three branded drug Solodyn and will also now exclude Retin-A brand, its number four branded drug, Wells Fargo analyst David Maris tells investors in a research note. The analyst estimates the two drugs represented approximately $214M of Valeant's sales in 2016. Maris also points out that Glumetza, Valeant's number eight branded drug, and Relistor were removed in July from CVS/Caremark's (CVS) formulary. These two drugs had approximately $119M in 2016 revenues. Maris notes his counterpart Peter Costa estimates that United Healthcare covers approximately 17% of the U.S. and CVS covers approximately 33%. Express Scripts (ESRX) is releasing its 2018 national formulary next week, Costa adds. Maris keeps an Underperform rating on shares of Valeant with a $9 price target. The stock in premarket trading is down 33c, or 2%, to $16.80.
08/04/17
WELS
08/04/17
NO CHANGE
WELS
Underperform
Valeant's Isuprel to face generic from Nexus, says Wells Fargo
Wells Fargo analyst David Maris noted that the FDA is reporting, and Nexus Pharmaceuticals has confirmed to him, that the company received approval for a generic version of Valeant's Isuprel. Nexus expects to "command the lion's share" of the U.S. market for the drug, as its version is made in the U.S. and has longer stability than Valeant's version, Maris tells investors. The analyst, who notes that Valeant previously indicated it anticipated that Isuprel would lose exclusivity in Q4, keeps an Underperform rating on the stock.

TODAY'S FREE FLY STORIES

09:37
06/20/18
06/20
09:37
06/20/18
09:37
Conference/Events
House Financial Services Committee to hold a hearing »

The Terrorism &…

MKSI

MKS Instruments

$103.90

(0.00%)

, SSNLF

Samsung

$0.00

(0.00%)

09:36
06/20/18
06/20
09:36
06/20/18
09:36
Recommendations
MKS Instruments, Samsung analyst commentary  »

MKS Instruments offers…

MKSI

MKS Instruments

$103.90

(0.00%)

SSNLF

Samsung

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

09:35
06/20/18
06/20
09:35
06/20/18
09:35
General news
U.S. existing home sales preview: »

U.S. existing home sales…

GE

General Electric

$12.96

(0.00%)

09:34
06/20/18
06/20
09:34
06/20/18
09:34
Recommendations
General Electric analyst commentary  »

GE's 'here to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBUX

Starbucks

$57.43

(0.00%)

09:34
06/20/18
06/20
09:34
06/20/18
09:34
Hot Stocks
Johnson says 'not immune' to geopolitical events, focused on long-term in China »

Starbucks CEO Kevin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

09:31
06/20/18
06/20
09:31
06/20/18
09:31
Conference/Events
House Financial Services Committee to hold a hearing »

The Committee holds a…

AMZN

Amazon.com

$1,735.74

(0.00%)

, JPM

JPMorgan

$107.58

(0.00%)

09:31
06/20/18
06/20
09:31
06/20/18
09:31
Hot Stocks
Amazon-Berkshire-JPMorgan healthcare joint venture names Atul Gawande CEO »

Amazon (AMZN), Berkshire…

AMZN

Amazon.com

$1,735.74

(0.00%)

JPM

JPMorgan

$107.58

(0.00%)

BRK.A

Berkshire Hathaway

$286,260.00

(0.00%)

BRK.B

Berkshire Hathaway

$190.38

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 13

    Jul

  • 12

    Oct

ITRI

Itron

$58.50

(0.00%)

, SPKE

Spark Energy

$10.30

(0.00%)

09:31
06/20/18
06/20
09:31
06/20/18
09:31
Recommendations
Itron, Spark Energy analyst commentary  »

Itron added to Best Ideas…

ITRI

Itron

$58.50

(0.00%)

SPKE

Spark Energy

$10.30

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOG

Harley-Davidson

$44.72

(0.00%)

09:31
06/20/18
06/20
09:31
06/20/18
09:31
Recommendations
Harley-Davidson analyst commentary  »

Harley-Davidson trends…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:30
06/20/18
06/20
09:30
06/20/18
09:30
General news
The U.S. current account gap widened »

The U.S. current account…

VHC

VirnetX

$3.45

(0.00%)

09:29
06/20/18
06/20
09:29
06/20/18
09:29
Hot Stocks
VirnetX enters reseller agreement with Above PAR Advisors »

VirnetX has entered into…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTCT

PTC Therapeutics

$33.21

(0.00%)

, SRPT

Sarepta

$143.92

(0.00%)

09:27
06/20/18
06/20
09:27
06/20/18
09:27
Recommendations
PTC Therapeutics, Sarepta analyst commentary  »

PTC Therapeutics weakness…

PTCT

PTC Therapeutics

$33.21

(0.00%)

SRPT

Sarepta

$143.92

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 20

    Jun

AMZN

Amazon.com

$1,735.74

(0.00%)

, BRK.A

Berkshire Hathaway

$286,260.00

(0.00%)

09:25
06/20/18
06/20
09:25
06/20/18
09:25
Hot Stocks
Breaking Hot Stocks news story on Amazon.com, Berkshire Hathaway, Berkshire Hathaway, JPMorgan »

Amazon, Berkshire,…

AMZN

Amazon.com

$1,735.74

(0.00%)

BRK.A

Berkshire Hathaway

$286,260.00

(0.00%)

BRK.B

Berkshire Hathaway

$190.38

(0.00%)

JPM

JPMorgan

$107.58

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 13

    Jul

  • 12

    Oct

TLGT

Teligent

$3.70

(0.00%)

09:25
06/20/18
06/20
09:25
06/20/18
09:25
Hot Stocks
Teligent announces FDA approval of Fluocinonide Gel, 0.05% »

Teligent announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPGI

S&P Global

$207.24

(0.00%)

, TST

TheStreet

$1.78

(0.00%)

09:25
06/20/18
06/20
09:25
06/20/18
09:25
Hot Stocks
S&P Global confirms purchase of RateWatch business from TheStreet »

S&P Global (SPGI)…

SPGI

S&P Global

$207.24

(0.00%)

TST

TheStreet

$1.78

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:25
06/20/18
06/20
09:25
06/20/18
09:25
General news
FX Action: USD-CAD »

FX Action: USD-CAD topped…

AZZ

AZZ Inc.

$44.93

(0.00%)

09:25
06/20/18
06/20
09:25
06/20/18
09:25
Conference/Events
House Energy & Commerce Committee to hold a hearing »

The Energy Subcommittee…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTEX

Mannatech

$20.40

(0.00%)

09:24
06/20/18
06/20
09:24
06/20/18
09:24
Hot Stocks
Mannatech announces final results of modified Dutch auction tender offer »

Mannatech announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FANG

Diamondback Energy

$127.56

(0.00%)

09:23
06/20/18
06/20
09:23
06/20/18
09:23
Recommendations
Diamondback Energy analyst commentary  »

Diamondback Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBUX

Starbucks

$57.43

(0.00%)

09:23
06/20/18
06/20
09:23
06/20/18
09:23
Hot Stocks
Starbucks CEO says 'some canibalization,' new entrants hurt China SSS in Q3 »

Starbucks CEO Kevin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

EMCI

EMC Insurance

$27.28

(0.00%)

09:23
06/20/18
06/20
09:23
06/20/18
09:23
Upgrade
EMC Insurance rating change  »

EMC Insurance upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KIN

Kindred Biosciences

$10.00

(0.00%)

09:20
06/20/18
06/20
09:20
06/20/18
09:20
Syndicate
Kindred Biosciences 4.632M share Spot Secondary priced at $9.50 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

RUT

Russell 2000 Index

$0.00

(0.00%)

, IWM

iShares Trust Russell 2000 Index Fund

$168.64

(0.00%)

09:20
06/20/18
06/20
09:20
06/20/18
09:20
Technical Analysis
Technical Take: iShares Trust Russell 2000 Index Fund hits new life high »

In pre-market trading the…

RUT

Russell 2000 Index

$0.00

(0.00%)

IWM

iShares Trust Russell 2000 Index Fund

$168.64

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBUX

Starbucks

$57.43

(0.00%)

09:19
06/20/18
06/20
09:19
06/20/18
09:19
Hot Stocks
Starbucks CEO sees transitioning to 'growth at scale' phase »

Starbucks CEO Kevin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

FEYE

FireEye

$16.99

(0.00%)

09:19
06/20/18
06/20
09:19
06/20/18
09:19
Hot Stocks
FireEye and Gigamon partner in security services »

FireEye and Gigamon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.